Pharmacy news

• Deutetrabenazine Response Can Emerge After 15 Weeks, Post Hoc Analysis Suggests

  08-10-2026 03:14 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon GroupBy Gina ShawNearly one-fourth of patients with tardive
  
  Read more

• Brief Caregiver Education Boosts TD Evaluation and Diagnosis

  10-10-2026 02:18 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By Gina ShawA single 10- to 15-minute online education
  
  Read more

• FDA Approves Extended-Release Form of Olanzapine for Treatment of Schizophrenia

  09-10-2026 14:24 via pharmacypracticenews.com
  
  By PPN StaffThe FDA approved olanzapine as an extended-release injectable suspension (Weltruza, Teva) for the treatment of schizophrenia in adults.With the approval, the drug becomes the first and only once-monthly subcutaneous long-acting injectable formulation of olanzapine for the treatment of schizophrenia in adults. It does not require loading doses, oral supplementation, or post-injection monitoring.Extended-release injectable olanzapine “combines proven science and novel formulation
  
  Read more

• FDA Approves Remibrutinib for Treatment-Resistant Symptomatic Dermographism

  09-10-2026 13:53 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By PPN StaffThe FDA approved remibrutinib (Rhapsido, N
  
  Read more

• Advertisement

• Registry Data Support Treating Mild Tardive Dyskinesia

  09-10-2026 02:16 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon GroupBy Gina ShawPatients whose tardive dyskinesia (TD) rate
  
  Read more

• Pharmacy-Led Revenue Cycle Work Closes Billing Gaps, Speeds Treatment

  08-10-2026 12:00 via pharmacypracticenews.com
  
  figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon GroupBy Gina ShawPharmacists are well positioned to lead revenue cycle management for infused medications because they can follow a dru
  
  Read more

• In-House Pharmacy Benefit Flattens Costs, Keeps Employees on GLP-1s

  08-10-2026 12:00 via pharmacypracticenews.com
  
  figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By Gina ShawAfter Beth Israel Lahey Health (BILH) brought its employee prescription benefit in-house and began requiring employee
  
  Read more

• FDA Approves Degevma, Biosimilar to Xgeva

  07-10-2026 15:02 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy SPC StaffThe FDA approved the biosimilar Degevma (denosumab-adet, Teva) for all indications of its reference product, Xgeva (denosumab, Amgen). These include:• preventing bone complications in adults with advanced cancer that has spread to the bone;• treating adults and skeletally mature adolescents with giant cell tumor of bone; and• treating hypercalcemia of malignancy.Degevma is Teva’s second bi
  
  Read more

• Advertisement

• Financial Success Hinges on Proactive Enterprise Planning

  07-10-2026 11:00 via pharmacypracticenews.com
  
  figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }McMahon Group.By Gina ShawHealth systems are looking to pharmacy to strengthen their finances, but many lack tools to track 340B performance or dedic
  
  Read more

• AAM Report: Generics and Biosimilars Saved $496 Billion in 2025

  06-10-2026 04:45 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Fran KritzGeneric and biosimilar drugs jointly created $496 billion in savings in 2025 for the U.S. healthcare system and for patients, according to a new report released by the Association for Accessible Medicines and the Biosimilars Council. Savings over the last decade were $3.5 trillion.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure im
  
  Read more

• Innovative Oral Anticancer Therapy Monitoring In Health-System Specialty Pharmacy

  05-10-2026 03:30 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumKristen Whelchel, PharmD, CSPProgram Director, Patient Care ImprovementBrooke Looney, PharmD, CSPClinical Specialty PharmacistStephanie White, PharmD, CSPClinical Specialty PharmacistAutumn D. Zuckerman, PharmD, BCPS, CSPDirector, Health Outcomes and ResearchVanderbilt Specialty PharmacyVanderbilt HealthNashville, TennesseeThe growing use of oral anticancer medications (OAMs) has enabled many patients to receive effective
  
  Read more

• Closing the Rx Gap Between Oncology Guidelines and Practice

  04-10-2026 03:30 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Marcus A. BanksPersonalized oncology care depends on timely biomarker and genetic testing to guide treatment, but those tests are not always performed when patients need them, speakers said at Asembia’s AXS26 Summit, in Las Vegas. For specialty pharmacists, that gap represents both a patient-care challenge and a call to action: Help identify access barriers, reinforce appropriate testing and treatment pathways, a
  
  Read more

• The Ongoing Struggle of Sickle Cell Disease

  03-10-2026 02:30 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Karen BlumPatients with sickle cell disease (SCD) still face challenges with pain and fatigue as well as gaining access to a new gene therapy, according to two new studies.The first study found that acute pain and fatigue experienced by people with SCD are associated with higher costs and healthcare resource utilization—to the tune of an additional $7,689 higher per patient per year over counterparts who don&rsqu
  
  Read more

• AHA Comments on 340B Pending Legislation, Urges Barring Rebate Models

  02-10-2026 04:18 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Fran KritzThe American Hospital Association (AHA) submitted comments on Sept. 23 regarding the Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act (SECURE 340B Act). The bill was introduced in July and, if passed, would make significant statutory changes to the 340B Drug Pricing Program.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-si
  
  Read more

• FDA Approves Juvmo for Parkinson’s Disease

  01-10-2026 09:27 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy SPC StaffThe FDA approved tavapadon (Juvmo, AbbVie) tablets for adults with Parkinson’s disease. The drug is the first selective D1/D5 receptor agonist approved for the disease.The approval was based on data from the TEMPO-3 trial (ClinicalTrials.gov Identifer: NCT04542499) published in JAMA Neurology (2026;83;[5]:442-451).“Development of motor fluctuations is common in people with [Parkinson’s diseas
  
  Read more

• What You Should Know About This Hep C Pipeline Drug

  30-09-2026 11:34 via pharmacypracticenews.com
  
  By Meaghan Lee CallaghanA new investigational drug for the treatment of hepatitis C could one day give clinicians an option that has fewer drug–drug interactions and only an eight-week treatment duration.Janet Hammond, MD, PhD, the chief development officer at Atea Pharmaceuticals, in Boston, sat down with Infectious Disease Special Edition to talk about their new drug in development, a combination of bemnifosbuvir and ruzasvir. Recent research presented at EASL 2026 (poster FRI-635)
  
  Read more

• FDA Approves Ustekinumab for Children With IBD

  29-09-2026 11:26 via pharmacypracticenews.com
  
  Originally published by our sister publication Gastroenterology & Endoscopy NewsBy Katie PrinceThe FDA has approved ustekinumab (Stelara, Johnson & Johnson) for the treatment of children as young as 2 years of age with moderate to severe ulcerative colitis.Ustekinumab, which was approved to treat moderate to severe Crohn’s disease in this population in April, is the first biologic non–tumor necrosis factor inhibitor approved for pediatric patients with inflammatory bowel dise
  
  Read more

• Amneal Announces FDA Approval and Launch of Lanreotide Injection

  28-09-2026 19:21 via pharmacypracticenews.com
  Amneal Pharmaceuticals, Inc. announced that the FDA has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product references SOMATULINE® Depot and will launch immediately. The product received Competitive Generic Therapy (CGT) designation from the FDA.“The approval and launch of lanreotide adds another material growth driver to our Affordable Medicines business,” said Srinivas Kone, PhD, senior vice president and chief scientific o
  
  Read more

• Germfree Expands IV Pharmacy Capabilities through Certified Integration of Smarthood with Wolters Kluwer Simplifi+ IV Workflow

  28-09-2026 19:14 via pharmacypracticenews.com
  Germfree Laboratories, LLC, a pioneering leader in modular and mobile cleanroom infrastructure, announced the certified integration of its Smarthood™ sterile compounding hood with Wolters Kluwer Health’s Simplifi+® IV Workflow Management with Assure-Trak® and Simplifi 797® solutions. The integration includes full hardware and software compatibility for highly accurate measurements with both volumetric and gravimetric workflows, allowing pharmacy teams to complete required
  
  Read more

• Genomic Test Identifies Breast Cancer Patients With Minimal Benefit From Chemotherapy

  28-09-2026 11:21 via pharmacypracticenews.com
  
  Originally published by our sister publication Clinical Oncology NewsBy Jennifer KulpaUse of a 50-gene genomic test identified patients with high-clinical-risk, estrogen receptor–positive (ER+), HER2-negative early breast cancer who could safely avoid chemotherapy without increasing their risk for relapse or death, according to findings from the phase 3 OPTIMA trial.Trial DesignFor OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis), the investigat
  
  Read more

• Selpercatinib Receives Traditional Approval for RET Fusion–Positive Solid Tumors

  27-09-2026 11:22 via pharmacypracticenews.com
  
  Originally published by our sister publication Clinical Oncology NewsBy Natasha Albaneze, MPHSelpercatinib (Retevmo, Lilly) was granted approval by the FDA to treat locally advanced or metastatic RET fusion–positive solid tumors in patients at least 2 years of age who have received prior systemic treatment.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:blo
  
  Read more

• New Teva Resource Aims to Move LAIs Earlier in Schizophrenia Care

  25-09-2026 16:12 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }liaksandr Marko, alexkoral - stock.adobe.comBy Gina ShawTeva has launched
  
  Read more

• Specialty Pharmacy Teams Can Play Helpful Roles in Lupus Management

  25-09-2026 15:10 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Karen BlumSystemic lupus erythematosus (SLE), or lupus, is difficult to diagnose. Fortunately, specialty pharmacy teams can find updated treatment information through a guideline released in 2025 and help patients in multiple ways, an SLE expert noted during the National Association of Specialty Pharmacy’s inSPire2026 meeting, in National Harbor, Maryland.“The course of the disease is marked by flares and p
  
  Read more

• RFID Can Help Hospitals Control High-cost Medication Inventories

  25-09-2026 04:02 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Robert HowardHospitals are under growing pressure to manage increasingly complex and costly medication inventories. Specialty drugs, biologics, and other high-value therapies represent a significant and expanding share of pharmacy budgets, yet many health systems still lack real-time visibility into where these medications are stored, how they are being used, and whether they are being protected from loss or waste. As
  
  Read more

• Pharmacies a Hot Target for Phishing, Vishing, and Other Cyberattacks

  24-09-2026 18:54 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }Studio KN – stock.adobe.comBy Karen BlumImagine this scenario: You c
  
  Read more

• Quality Specialty Pharmacy Programs Need Data, Dedicated Staffs

  24-09-2026 17:00 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }StratfordProductions - stock.adobe.comBy Karen BlumDesigning a quality spe
  
  Read more

• When Law Enforcement Comes Knocking, Be Prepared

  24-09-2026 12:35 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }Studio KN – stock.adobe.comBy Karen BlumIf representatives from the
  
  Read more

• Cold Chain Shipping: Why Pharmacies Struggle and How to Strengthen Compliance

  23-09-2026 19:00 via pharmacypracticenews.com
  
  figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }Credit: Grispb – stock.adobe.com.By Karen Spano, RPh, HDDPAcross pharmacy settings—from independent and hospital pharmacies to large nati
  
  Read more

• New URAC Accreditation Offers Path to AI Implementation With Oversight

  23-09-2026 15:40 via pharmacypracticenews.com
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Marcus A. BanksThis summer, URAC introduced its Health Care AI Accreditation to establish standards for responsible deployment of artificial intelligence. A speaker from one of the first recipients of the new accreditation discussed how AI can, with guardrails, improve pharmacy operations and patient experience at the National Association of Specialty Pharmacy’s inSPire2026 meeting, in National Harbor, Maryland.f
  
  Read more

• What to Know About Bixlenvo for HIV

  23-09-2026 12:11 via pharmacypracticenews.com
  
  By Meaghan Lee Callaghan What do you know about the newly approved HIV combination drug bictegravir/lenacapavir (Bixlenvo, Gilead)?Following the new FDA approval, Onyema Ogbuagu, MBBCh, MD, a professor at Yale University, in New Haven, sat down with Infectious Disease Special Edition to talk about the drug. Dr. Ogbuagu, who is also the director of the Yale Antivirals and Vaccines Research Program (formerly HIV Clinical Trials program), should know best—he was a study investigator
  
  Read more

Follow @newsl_pharmacy on Twitter!